4 days ago · BEDFORD, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen ...

4 days ago · Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...

3 days ago · Lantheus has reached an agreement to acquire radiopharmaceutical firm Evergreen Theragnostics for up to $1 billion, the two announced Tuesday. Founded in 2019 and headquartered in Springfield, New Jersey, Evergreen develops and manufactures imaging agents aimed at diagnosing and treating cancer.

4 days ago · For more information, visit www.lantheus.com. About Evergreen Theragnostics, Inc. Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in Contract Development and Manufacturing (CDMO) services as well as drug discovery and commercialization of proprietary ...

4 days ago · Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader

3 days ago · On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional ...

3 days ago · The Bedford company announced its acquisition of Evergreen Theragnostics Inc. Tuesday. Lantheus (Nasdaq: LNTH) is paying $250 million upfront in the all-cash transaction, plus up to an additional ...

3 days ago · New York – January 28, 2025 – Cooley advised Lantheus Holdings (Nasdaq: LNTH), a radiopharmaceutical-focused company committed to enabling clinicians to find, fight and follow disease to deliver better patient outcomes, on its definitive agreement to acquire Evergreen Theragnostics.Under the terms of the agreement, Lantheus will pay an upfront amount of $250 million in cash at closing and ...

4 days ago · Lantheus acquires Evergreen Theragnostics for $250M upfront payment; Lantheus still sees 2024 EPS $6.65-$6.70, consensus $6.75; Lantheus Acquires Life Molecular Imaging for $350 Million; Lantheus ...

3 days ago · Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced Tuesday morning, Evergreen is also set to receive up to $752.5 million in potential milestone payments for Octevy as well as its clinical and pre ...